---
title: "Guotai Junan Securities initiates coverage on KEYMED BIO with a \"Buy\" rating and a target price of 83.29 yuan"
description: "Guojin Securities initiates coverage on KEYMED BIO-B with a \"Buy\" rating and a target price of HKD 83.29. It forecasts operating revenues of RMB 661 million, RMB 1.255 billion, and RMB 2.064 billion f"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270947406.md"
published_at: "2025-12-29T03:35:08.000Z"
---

# Guotai Junan Securities initiates coverage on KEYMED BIO with a "Buy" rating and a target price of 83.29 yuan

> Guojin Securities initiates coverage on KEYMED BIO-B with a "Buy" rating and a target price of HKD 83.29. It forecasts operating revenues of RMB 661 million, RMB 1.255 billion, and RMB 2.064 billion for 2025 to 2027, with annual growth rates of 54%, 90%, and 65%, respectively. Dupilumab, as the second IL-4R monoclonal antibody globally and the first in China, has been included in the national medical insurance catalog, expected to be implemented in early 2026, with sales expected to grow rapidly

Guojin Securities published a report, initiating coverage on KEYMED BIO-B (02162.HK) with a "Buy" rating and a target price of HKD 83.29. The firm predicts that the company will achieve operating revenues of RMB 661 million, 1.255 billion, and 2.064 billion for the years 2025 to 2027, representing year-on-year growth of 54%, 90%, and 65%, respectively. During this period, it is expected to incur losses of RMB 513 million, RMB 297 million, and turn a profit of RMB 201 million, corresponding to a loss per share of RMB 1.72, a loss per share of RMB 0.99, and earnings per share of RMB 0.67.

The report indicates that the company has a deep layout in differentiated self-immune chronic diseases and oncology tracks, with numerous pipelines under research. The core product, Suptavumab, has been approved for market launch, and CM512 (TSLP/IL-13 dual antibody) is currently expanding into multiple Phase II clinical trials. The authorized CMG901 from AZ is expected to submit an NDA in the U.S. in 2026. The early research layout includes multiple technology platforms, and the pipeline is expected to advance gradually, with ample backup strength. Suptavumab, as the first domestically produced IL-4R monoclonal antibody, has a clear first-mover advantage and is expected to see rapid volume growth after the implementation of medical insurance in 2026. The IL-4R monoclonal antibody can target various type II inflammatory diseases such as atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, only two IL-4R monoclonal antibodies have been approved globally, with Sanofi's Dupilumab rapidly gaining market share since its launch in 2017 and continuously expanding new indications, with global sales expected to exceed USD 14 billion in 2024.

The report states that Suptavumab, as the second IL-4R monoclonal antibody globally and the first in China, has a clear first-mover advantage and shows better efficacy compared to Dupilumab in non-head-to-head comparisons. It has already been approved for three indications (AD, CRSwNP, allergic rhinitis SAR, with the latter two being exclusive indications). Suptavumab has been included in the national medical insurance catalog for December 2025, with implementation expected in early 2026, and is anticipated to see rapid volume growth after entering medical insurance. Since its launch in September 2024, sales for the first half of 2024 and 2025 are expected to be RMB 36 million and RMB 169 million, respectively, with projected sales for 2025 to 2027 expected to reach RMB 331 million, RMB 905 million, and RMB 1.627 billion, respectively

### Related Stocks

- [02162.HK - KEYMED BIO-B](https://longbridge.com/en/quote/02162.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 川普宣佈派醫療船赴格陵蘭 | 美國總統川普宣佈派遣一艘醫療船前往格陵蘭，稱該地對美國及北約在應對俄羅斯與中國方面的安全至關重要。川普表示這艘船將幫助格陵蘭的「生病的人」，但未透露具體情況。此舉加劇了美國與丹麥的緊張關係，並引發全球對北極地區的關注。川普在社交媒體上發布了 | [Link](https://longbridge.com/en/news/276537732.md) |
| 川普揚言發動有限軍事打擊 伊朗：將視為侵略行徑 | 在美國總統川普聲稱考慮對伊朗發動有限軍事打擊後，伊朗表示，任何攻擊，包括有限打擊，都會被視為「侵略行徑」，並將予以回應。伊朗外交部發言人貝卡伊強調，任何國家都有權以自衞回應侵略。 | [Link](https://longbridge.com/en/news/276594257.md) |
| 中國白銀集團 (0815) 折讓 18% 配股籌 4.6 億 | 中國白銀集團宣佈將向 6 名認購人發行 9.1 億股認購股份，折讓約 17.74%，每股認購價為 0.51 元，籌集資金總額為 4.641 億元。所得款項將用於日喀則礦的資本開支、進一步融資及一般營運資金。 | [Link](https://longbridge.com/en/news/276432450.md) |
| 【黃金收評】川普對伊朗下最後通牒！金價醖釀下一波大行情 接下來如何交易？ | 週四現貨黃金收盤上漲 0.37%，報 4995.77 美元/盎司，受地緣政治風險支撐，但強勢美元和美聯儲鷹派立場限制漲幅。川普警告伊朗必須在 10 至 15 天內達成核協議，否則將面臨嚴重後果。美軍在該地區集結兵力，金價在過去兩日累計上漲超 | [Link](https://longbridge.com/en/news/276498546.md) |
| 環保政策大轉向 川普政府鬆綁燃煤電廠排放 | 美國川普政府決定廢除拜登政府針對燃煤和燃油發電廠的嚴格環境標準，稱此舉將恢復美國的能源主導地位。環保署表示新政策將保護公眾健康，但環保團體警告此舉將增加心肺疾病和癌症風險。川普政府認為拜登的規定對煤炭行業造成負擔，而環保組織則認為此舉是削弱 | [Link](https://longbridge.com/en/news/276518836.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.